Quick Answer
MiNK Therapeutics, Inc. reported Net Income of -$12.49 million for fiscal year 2025.
MiNK Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$12.49M -15.9% |
-$10.78M +52.0% |
-$22.46M +19.8% |
-$27.99M +7.4% |
-$30.21M -86.1% |
-$16.24M |
| Diluted EPS | -$2.93 -2.4% |
-$2.86 +56.3% |
-$6.54 -688.0% |
-$0.83 +28.4% |
-$1.16 | — |
| Total Assets | $14.24M +148.9% |
$5.72M +25.7% |
$4.55M -78.8% |
$21.47M -46.6% |
$40.24M +783.4% |
$4.56M |
| Cash and Equivalents | $13.36M +191.9% |
$4.58M +35.9% |
$3.37M -82.9% |
$19.64M -49.5% |
$38.89M | — |
| Stockholders Equity | -$14.23M +27.4% |
-$19.59M -8.5% |
-$18.06M -4399.2% |
-$401.3K -101.7% |
$23.78M +144.1% |
-$53.87M -48.3% |
| R&D Expense | $5.76M -9.1% |
$6.34M -59.1% |
$15.49M -33.0% |
$23.12M +65.5% |
$13.97M +46.9% |
$9.51M |
| Operating Income | -$12.64M -12.0% |
-$11.29M +50.8% |
-$22.92M +25.9% |
-$30.95M -9.1% |
-$28.36M -93.7% |
-$14.64M |
| Shares Outstanding | — | 3.96M +14.5% |
3.46M -89.8% |
33.86M +1.1% |
33.48M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$2.89M | -59.8% | +31.9% |
| Diluted EPS | September 30, 2025 | -$0.65 | -41.3% | +38.7% |
| Total Assets | September 30, 2025 | $14.96M | +102.9% | +502.3% |
| Cash and Equivalents | September 30, 2025 | $14.28M | +125.7% | +749.1% |
| Stockholders Equity | September 30, 2025 | -$13.51M | +23.0% | +46.4% |
| R&D Expense | September 30, 2025 | $1.14M | +111.4% | -37.8% |
| Operating Income | September 30, 2025 | -$3.18M | -68.9% | +21.4% |
- MiNK Therapeutics, Inc. reported Net Income of -$12.49 million for fiscal year 2025.
- MiNK Therapeutics, Inc. showed a decrease of -15.9% in Net Income compared to the prior fiscal year.
- MiNK Therapeutics, Inc. reported Diluted EPS of $2.93 per share (loss) for fiscal year 2025.
- MiNK Therapeutics, Inc. showed a decrease of -2.4% in Diluted EPS compared to the prior fiscal year.
- MiNK Therapeutics, Inc. reported Total Assets of $14.24 million for fiscal year 2025.
- MiNK Therapeutics, Inc. showed an increase of +148.9% in Total Assets compared to the prior fiscal year.
- MiNK Therapeutics, Inc. reported Cash and Equivalents of $13.36 million for fiscal year 2025.
- MiNK Therapeutics, Inc. showed an increase of +191.9% in Cash and Equivalents compared to the prior fiscal year.
- MiNK Therapeutics, Inc. reported Stockholders Equity of -$14.23 million for fiscal year 2025.
- MiNK Therapeutics, Inc. showed an increase of +27.4% in Stockholders Equity compared to the prior fiscal year.
- MiNK Therapeutics, Inc. reported R&D Expense of $5.76 million for fiscal year 2025.
- MiNK Therapeutics, Inc. showed a decrease of -9.1% in R&D Expense compared to the prior fiscal year.
- MiNK Therapeutics, Inc. reported Operating Income of -$12.64 million for fiscal year 2025.
- MiNK Therapeutics, Inc. showed a decrease of -12.0% in Operating Income compared to the prior fiscal year.
- MiNK Therapeutics, Inc. reported Shares Outstanding of 3.96 million shares for fiscal year 2024.
- MiNK Therapeutics, Inc. showed an increase of +14.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: